Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term antibody persistence after Hib-MenC booster versus Infanrix hexa booster in 14-month-old children
2006-000518-19Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Hib-MenC-TT and pertussis filamentous haemagglutinin in Haemophilus influenzae type b disease (Hib) and meningococcal group C disease (2 arms), sponsored by GSK. Primary endpoint: Persistence of meningococcal C antibodies. Started Jun 2012; status: completed.
02
Drugs
Hib-MenC-TTpertussis filamentous haemagglutinin
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal group C disease
Beyond the preview
Go deeper on 2006-000518-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000518-19.